Evidence map›Paper›PMID 39703517›Full record

ArticleFrontiers in immunology2024

Cryoablation of primary breast cancer tumors induces a systemic abscopal effect altering TIME (Tumor Immune Microenvironment) in distant tumors.

Flávia Sardela de Miranda, Dalia Martinez-Marin, Rachel L Babcock, Maribel Castro, Geetha P Boligala, Sonia Y Khan, Kathryn L Furr, Isabel Castro-Piedras, Nicholas Wagner, Dakota E Robison and 5 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Flávia Sardela de MirandaDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Dalia Martinez-MarinDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Rachel L BabcockBreast Center of Excellence, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Maribel CastroDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Geetha P BoligalaDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Sonia Y KhanDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Kathryn L FurrDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Isabel Castro-PiedrasDepartment of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Nicholas WagnerDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Dakota E RobisonDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Karla DanieleDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Sharda P SinghBreast Center of Excellence, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Kevin PruittDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Michael W MelkusDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Rakhshanda Layeequr RahmanDepartment of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.

Funding

CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
NCI NIH HHS T32 CA196589
6 · The paper itself

Abstract

Introduction: Despite recent advances, triple-negative breast cancer (TNBC) patients remain at high risk for recurrence and metastasis, which creates the need for innovative therapeutic approaches to improve patient outcomes. Cryoablation is a promising, less invasive alternative to surgical resection, capable of inducing tumor necrosis via freeze/thaw cycles. Necrotic cell death results in increased inflammatory signals and release of preserved tumor antigens, which have the potential to boost the local and systemic anti-tumor immune response. Thus, compared to surgery, cryoablation enhances the activation of T cells leading to an improved abscopal effect, defined as the occurrence of a systemic response after local treatment. We previously showed with a bilateral-tumor mouse model of TNBC that cryoablation of the primary tumor leads to increased infiltration of distant (abscopal) tumors by tumor infiltrating lymphocytes (TILs) and decreased rates of recurrence and metastasis. However, the early drivers of the cryoablation generated abscopal effect are still unknown and knowledge of the mechanism could provide insight into improving the anti-tumor immune response through pharmacologic immune modulation in addition to cryoablation. Methods: One million 4T1-12B-luciferase expressing cells were transplanted into the mammary fat pad of BALB/c mice. Two weeks later, left (primary) tumors were either resected or cryoablated. A week after the procedure, right (abscopal) and left tumors, along with spleen, tumor-draining lymph node and blood were collected and processed for flow cytometry and/or RNA-sequencing and immunofluorescence. Results: Here we show that cryoablation of mouse mammary carcinomas results in smaller abscopal tumors that harbor increased frequencies of anti-tumor cells [such as natural killer (NK) cells], accompanied by a systemic increase in the frequency of migratory conventional type 1 dendritic cells (cDC1; CD103 Conclusions: These results better define the early mechanisms through which cryoablation improves tumor elimination, which is mediated by enhanced frequencies of anti-tumoral cells such as NK and cDC1s at the abscopal tumor and in the spleen of mice treated with cryoablation, respectively.

Indexed as

CryosurgeryLymphocytes, Tumor-InfiltratingTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CTriple Negative Breast Neoplasmsabscopal effectbreast cancercryoablationimmune responseRNA-seq analysis

Identifiers

PMID39703517
PMCPMC11657241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.